Literature DB >> 11750224

CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.

R D Weeratna1, C L Brazolot Millan, M J McCluskie, H L Davis.   

Abstract

Induction of an appropriate immune response is essential for successful immunization. For example, Th1 type immune responses are necessary for the control of intracellular infections whereas Th2 type responses are more useful for the control of extracellular infections. Immunostimulatory CpG ODN (oligonucleotides containing unmethylated cytosine and guanine dinucleotides in specific base contexts) act as potent adjuvants and have been shown to induce Th1 type immune responses with a number of different antigens. This study investigates the effect of CpG ODN on the Th bias of immune responses generated against the hepatitis B major surface antigen (HBsAg) in adult (6-8 weeks old) and young (<1 week old) BALB/c mice. It also investigates the potential of CpG DNA to reverse a pre-established Th2 response generated as an adult or as a neonate, following re-exposure to HBsAg in adult life. Both adult and young mice immunized with HBsAg/CpG ODN had a Th1 biased immune response (strong cytotoxic T-lymphocyte (CTL) induction, IgG2a>>IgG1). In contrast, mice immunized with HBsAg/alum had a Th2 type immune response (poor CTL, IgG1>>IgG2a). More importantly, when animals were immunized with HBsAg/alum and boosted with HBsAg/CpG ODN, the CpG ODN were able to re-direct the Th2 response pre-established by alum, whereas the animals receiving the primary immunization with HBsAg/CpG ODN and later boosted with HBsAg/alum maintained their Th1 bias, even after the boost with alum. These data suggest that CpG ODN have the ability to augment both humoral and cell mediated immune responses and override the Th2 bias created by alum, even in very young animals, which are known to have a Th2 biased immune system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11750224     DOI: 10.1111/j.1574-695X.2001.tb00535.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  34 in total

Review 1.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

2.  Interferon-gamma priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages.

Authors:  Miriam V Liscovsky; Romina P Ranocchia; Carolina V Gorlino; Diego O Alignani; Gabriel Morón; Belkys A Maletto; María C Pistoresi-Palencia
Journal:  Immunology       Date:  2008-09-17       Impact factor: 7.397

Review 3.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

Review 4.  Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.

Authors:  Kosuke Kataoka; Yoshiko Fukuyama; David E Briles; Tatsuro Miyake; Kohtaro Fujihashi
Journal:  Microbiol Immunol       Date:  2017-06       Impact factor: 1.955

Review 5.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

6.  CpG-induced Th1-type response in the downmodulation of early development of allergy and inhibition of B7 expression on T cells of newborn mice.

Authors:  Cyro A de Brito; Ana E Fusaro; Jefferson R Victor; Paula O Rigato; Adriana L Goldoni; Bruno P Muniz; Alberto J S Duarte; Maria N Sato
Journal:  J Clin Immunol       Date:  2010-01-19       Impact factor: 8.317

7.  Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.

Authors:  Wenjun Xiao; Lanying Du; Chao Liang; Jie Guan; Shibo Jiang; Sara Lustigman; Yuxian He; Yusen Zhou
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

8.  Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.

Authors:  Ali Badiee; Mahmoud R Jaafari; Afshin Samiei; Dina Soroush; Ali Khamesipour
Journal:  Clin Vaccine Immunol       Date:  2008-01-30

9.  Failure of a VapA/CpG oligodeoxynucleotide vaccine to protect foals against experimental Rhocococcus equi pneumonia despite induction of VapA-specific antibody and interferon-γ response.

Authors:  Katharina L Lohmann; A Marianela Lopez; Stephen T Manning; Fernando J Marques; Robert Brownlie; Andrew L Allen; Anna E Sangster; George Mutwiri; Volker Gerdts; Andrew Potter; Hugh G G Townsend
Journal:  Can J Vet Res       Date:  2013-07       Impact factor: 1.310

10.  Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection.

Authors:  Linda J Berry; Danica K Hickey; Kathryn A Skelding; Shisan Bao; Amanda M Rendina; Philip M Hansbro; Christine M Gockel; Kenneth W Beagley
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.